Precision Oncology at Scale: Lantern Pharma’s Strategic Vision with CEO Panna Sharma

Lantern Pharma Inc. (Nasdaq: LTRN) is a clinical-stage biopharmaceutical company redefining oncology drug development through artificial intelligence. Its proprietary RADR® platform leverages over 200 billion oncology-specific data points to rapidly identify drug candidates, optimize patient targeting, and de-risk clinical trials—cutting early development time and cost by up to 70% and 80%, respectively. Lantern’s pipeline includes three clinical-stage assets: LP-300 (Phase 2) for NSCLC in never-smokers, LP-184 (Phase 1) for DDR-deficient solid tumors, and LP-284 (Phase 1) for aggressive B-cell lymphomas. The company also advances CNS oncology programs via its subsidiary Starlight Therapeutics and is developing novel antibody-drug conjugates (ADCs) in collaboration with global partners. With 11 FDA designations, over 100 issued and pending patents, and partnerships spanning Johns Hopkins, MD Anderson, and Bielefeld University, Lantern is positioned to unlock value through precision-driven clinical execution and strategic collaborations—all backed by $19.7 million in cash and a lean operating structure.Lantern Pharma is a client of RedChip. Visit RedChip.com to learn more.